B
Barker Andrew John
Researcher at AstraZeneca
Publications - 12
Citations - 1185
Barker Andrew John is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cyclin-dependent kinase & Epidermal growth factor. The author has an hindex of 10, co-authored 12 publications receiving 1138 citations.
Papers
More filters
Journal ArticleDOI
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
Barker Andrew John,Keith Hopkinson Gibson,Walter Grundy,Godfrey Andrew Aydon,Jeffrey J Barlow,Mark P Healy,J. R. Woodburn,Susan Ashton,Brenda Curry,Lynn Scarlett,Lianne Henthorn,Laura Richards +11 more
TL;DR: ZD 1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours and the use of pharmacokinetic data in the development of ZD1839 is discussed.
Patent
Quinazoline derivatives as antitumor agents
TL;DR: In this article, the quinazoline derivatives of formula (I) were introduced and processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
Journal ArticleDOI
Zd1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
J. R. Woodburn,Barker Andrew John,Keith Hopkinson Gibson,Susan Ashton,A. E. Wakeling,Brenda Curry,L. Scarlett,L. R. Henthorn +7 more
Journal ArticleDOI
Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines
Keith Hopkinson Gibson,Walter Grundy,Godfrey Andrew Aydon,J. R. Woodburn,Susan Ashton,Brenda Curry,L. Scarlett,Barker Andrew John,D. S. Brown +8 more
TL;DR: Investigation of structure-activity relationships of novel quinazolines has identified a 4-(4-iso-quinolylamino)-quinazoline and a 4-trans-2-phenylcyclopropylamino as potent inhibitors of EGF-receptor tyrosine kinase in vitro.
Patent
Indole derivatives and their use as mcp-1 antagonists
TL;DR: The use of a compound of formula (I) and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1) is described in this paper.